AstraZeneca Mexico – Ugo de Jacobis, President
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives. The company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). It is also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. In Mexico the company relies on manufacturing capabilities and a staff of 150 people.
Contact details
AstraZeneca S.A. de C.V.
Periférico Sur No. 4305, 5to piso
Col. Jardines de la Montaña, Del. Tlalpan
CP 14210 México DF
MEXICO
Tel: +52 (55) 5374 9600
Website: www.astrazeneca.com/mexico
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
There have been a lot of changes in the Mexican pharmaceutical industry in the last four to five years, most notably the new drug registration process being put in place.…
Brothers Juan José and Andrés Aguirre Salazar of Grupo Bruluart discuss recent developments in the group and the strategic approach behind Bruluart’s impressive growth, helping it to proudly stand as…
VP Mesoamerica at Siemens Healthineers, Alejandro Paolini, explains the crucial role of prevention capabilities in increasing patients’ probability of recovery and lowering treatment costs in Mexico. Further, he explains how…
Mario Muniz, general manager of Chiesi Mexico, explains how the affiliate looks at becoming a comprehensive solution provider in the neonatal field, highlights the dramatic consequences of the health budget…
Carolina Galicia explains how World Courier Mexico has strengthened its leadership position for clinical trials logistics and leveraged its cutting-edge transport and warehousing capacities to better meet the needs of…
Sandra Sánchez, General Manager at PROBIOMED, explains the crucial role that biosimilars will play in the future healthcare system as well as the importance of complying with COFEPRIS’ regulations to…
Gerardo Cárdenas Vogel, CEO of Innovare R&D, on transforming the company’s business model to benefit from drug development opportunities, Mexico as a world-class clinical trial destination, and new, innovative treatments…
In Mexico, more than 13 million people live with diabetes, while 71 percent of the total population have obesity or are overweight. Morten Vaupel, vice-president and general manager of Novo…
Raul Vivar, recently appointed GM of Eisai Mexico, describes the main achievements of the Japanese company in Mexico, the challenges that innovative companies face entering the Mexican market, and the…
Raúl Riquelme Cacho, president of the health commission of the Confederation of Industrial Chambers of the United Mexican States (CONCAMIN), reveals the recent alignment of CONCAMIN, which stands as the…
Efrén Ocampo, CEO of the Mexican pharmaceutical group Neolpharma, details the strategic thinking that has fostered the emergence of one of the most prominent healthcare groups in Mexico and the…
Hetero, the global API leader, has consolidated its position as the partner of choice of the pharmaceutical industry in Mexico, with a portfolio of more than 300 APIs. GM Gurulinga…
Fernando Oliveros, VP of Medtronic Mexico, explains how the global medical devices leader wants to leverage Covidien’s integration to improve health outcomes in Mexico. By taking advantage of an innovative…
See our Cookie Privacy Policy Here
